Blog

Prerna Mewawalla: Real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma

Prerna Mewawalla/findcare.ahn.org

Mar 10, 2025, 08:25

Prerna Mewawalla: Real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma

Prerna Mewawalla, Associate Professor at Drexel University, shared a post on X:

“My VuMedi presentation from Tandem2025 is live!

We explore real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma from the USMIRC study—highlighting the feasibility of CAR-T & bispecifics post-BCMA exposure.

Key insights from our research:

Sequential BCMA therapy remains feasible and effective.
No significant difference in PFS between CAR-T and bispecifics following Belantamab.
Prior BCMA exposure did not predict poor outcomes.

Would love to hear your experiences with BCMA sequencing in practice—how are you approaching it?

Watch here.”

belantamab cancer CAR-T Drexel University fight against cancer Global fight against cancer multiple myeloma OncoDaily Oncology Prerna Mewawalla Tandem2025 USMIRC study

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Daiichi Sankyo's and Astrazeneca's press release on ENHERTU®: Latest Updates from DESTINY-Gastric04 trial

13-year-old Cancer Survivor Sworn in as a Secret Service agent by President Trump - The White House

The European Parliament Intergroup on Cancer and Rare Diseases has been set in motion - ECO